| Low-carbohydrate diets and prostate cancer: how low is "low enough"? | |
| | |
MedLine Citation:
|
PMID: 20716631 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Previous studies indicate that carbohydrate intake influences prostate cancer biology, as mice fed a no-carbohydrate ketogenic diet (NCKD) had significantly smaller xenograft tumors and longer survival than mice fed a Western diet. As it is nearly impossible for humans to consume and maintain NCKD, we determined whether diets containing 10% or 20% carbohydrate kcal showed similar tumor growth as NCKD. A total of 150 male severe combined immunodeficient mice were fed a Western diet ad libitum, injected with the human prostate cancer cell line LAPC-4, and then randomized 2 weeks later to one of three arms: NCKD, 10% carbohydrate, or 20% carbohydrate diets. Ten mice not injected were fed an ad libitum low-fat diet (12% fat kcal) serving as the reference in a modified-paired feeding protocol. Mice were sacrificed when tumors reached 1,000 mm(3). Despite consuming extra calories, all mice receiving low-carbohydrate diets were significantly lighter than those receiving a low-fat diet (P < 0.04). Among the low-carbohydrate arms, NCKD-fed mice were significantly lighter than the 10% or 20% carbohydrate groups (P < 0.05). Tumors were significantly larger in the 10% carbohydrate group on days 52 and 59 (P < 0.05), but at no other point during the study. Diet did not affect survival (P = 0.34). There were no differences in serum insulin-like growth factor-I or insulin-like growth factor binding protein-3 at sacrifice among the low-carbohydrate arms (P = 0.07 and P = 0.55, respectively). Insulin was significantly lower in the 20% carbohydrate arm (P = 0.03). LAPC-4 xenograft mice fed a low-carbohydrate diet (10-20% carbohydrate kcal) had similar survival as mice consuming NCKD (0% carbohydrate kcal). |
| | |
Authors:
|
Elizabeth M Masko; Jean A Thomas; Jodi A Antonelli; Jessica C Lloyd; Tameika E Phillips; Susan H Poulton; Mark W Dewhirst; Salvatore V Pizzo; Stephen J Freedland |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. Date: 2010-08-17 |
Journal Detail:
|
Title: Cancer prevention research (Philadelphia, Pa.) Volume: 3 ISSN: 1940-6215 ISO Abbreviation: Cancer Prev Res (Phila) Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-03 Completed Date: 2010-12-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101479409 Medline TA: Cancer Prev Res (Phila) Country: United States |
Other Details:
|
Languages: eng Pagination: 1124-31 Citation Subset: IM |
Affiliation:
|
Duke University Medical Center, Box 2626, Durham, NC 27710, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
diet therapy*,
pathology Animals Body Weight / drug effects, physiology Diet, Carbohydrate-Restricted* / methods Dietary Carbohydrates / adverse effects, pharmacology* Dose-Response Relationship, Drug Energy Intake / physiology Graft Survival / drug effects Humans Ketogenic Diet / adverse effects Male Mice Mice, Inbred C57BL Mice, SCID Prostatic Neoplasms / diet therapy*, pathology Tumor Burden / drug effects Xenograft Model Antitumor Assays |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA131235/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Dietary Carbohydrates |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A dominant-negative c-jun mutant inhibits lung carcinogenesis in mice.
Next Document: Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice.